– TTP399, a novel glucokinase activator, achieves primary objective of a statistically significant reduction in HbA1c, without increases in hypoglycemia […]
HAIFA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a […]
FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for Management of Seizure ClustersPotential for First Oral Diazepam-Based Therapy for Population […]